<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon syndrome</z:e> is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> condition primarily characterized by <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This syndrome has been associated with a variety of amino acid point mutations in the extracellular domain of fibroblast growth factor receptor 2 (FGFR2) </plain></SENT>
<SENT sid="2" pm="."><plain>FGFR2/Neu chimeras were generated by substituting the extracellular domain of Neu with that of FGFR2 containing the following <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> mutations: Tyr-340--&gt;His; Cys-342--&gt;Tyr; Cys-342--&gt;Arg; Cys-342--&gt;Ser; Ser-354--&gt;Cys: and delta17 (deletion of amino acids 345-361) </plain></SENT>
<SENT sid="3" pm="."><plain>Each of the mutant chimeric FGFR2/Neu constructs stimulated focus formation in NIH 3T3 cells, indicating that <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> mutations can stimulate signal transduction through a heterologous receptor tyrosine kinase </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro kinase assay results indicate that FGFR2 receptors containing <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon</z:e> mutations have increased tyrosine kinase activity and, when analyzed under nonreducing conditions, exhibited <z:chebi fb="0" ids="48343">disulfide</z:chebi>-bonded dimers </plain></SENT>
<SENT sid="5" pm="."><plain>Thus the human developmental abnormality <z:e sem="disease" ids="C0010273" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Crouzon syndrome</z:e> arises from constitutive activation of FGFR2 due to aberrant intermolecular <z:chebi fb="0" ids="48343">disulfide</z:chebi>-bonding </plain></SENT>
<SENT sid="6" pm="."><plain>These results together with our earlier observation that <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> results from constitutive activation of the related receptor FGFR3, leads to the prediction that other malformation syndromes attributed to FGFRs, such as Pfeiffer syndrome and Thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, also arise from constitutive receptor activation </plain></SENT>
</text></document>